ArticleCVIR endovascular2025
Emergency endovascular treatment of stroke due to cervical artery dissection - impact of periprocedural GP IIb/IIIa inhibitor use on clinical outcome.
Article in CVIR endovascular, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndovascular therapy (EVT) for large intracranial vessel occlusion or symptomatic hypoperfusion due to cervical artery dissection (CeAD) became the standard therapy in recent years. Stenting is frequently required to secure the dissection with subsequent need for GP IIb/IIIa inhibitors. However, a potential concern of antithrombotic therapy in acute stroke is the increased risk of intracerebral hemorrhage. The aim of the study was to assess the impact of the administration of a GP IIb/IIIa inhibitor imaging during endovascular treatment for acute ischemic stroke caused by CeAD on 90-day clinical outcome and intracranial hemorrhage.
methodsThis single-center retrospective cohort study enrolled CeAD patients with internal carotid artery (ICA) dissections treated with EVT from January 2015 to August 2022. We analysed the impact of different variables including postinterventional hemorrhage, revascularization success and the use of GP IIb/IIIa Inhibitors (eptifibatide) on 90-day favorable clinical outcome (mRS 0-2). NIHSS Scores were evaluated at different time points in relation to the 90-day clinical outcomes.
resultsForty-nine patients were included in the study. Thrombectomy was performed in all patients. In 33 patients, stenting was performed in addition to thrombectomy. 20 patients (40.8%) received eptifibatide periinterventionally. 31 out of 49 patients (63.3%) had a favorable 90-day clinical outcome (mRS 0-2). Five patients showed radiologically significant hemorrhage. The rate of successful reperfusion (TICI 2b-3) in the favorable 90-day outcome group was significantly higher than in the unfavorable 90-day outcome group.
conclusionsIn this study, the use of a GP IIb/IIIa inhibitor use during EVT for stroke caused by CeAD did not affect 90-day clinical outcome nor the incidence of intracranial hemorrhage. Successful reperfusion significantly correlated with favorable clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.